IntroductionAdvanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas are characterized by an aggressive course and a very poor prognosis. Due to the limited benefit of immunotherapy in patients with HER2-negative tumors, new therapeutic t…
PurposedNatural Killer cell kinetics and Killer-cell immunoglobulin-like receptors (KIRs) are increasingly recognized for their role during allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the prognostic impact of donor KIR haplotype…
BackgroundTertiary lymphoid structures (TLSs) are increasingly regarded as important local immune niches in chronic inflammation and autoimmunity. However, a focused bibliometric overview of TLS research in autoimmune diseases is still lacking.MethodsP…
BackgroundPerioperative alterations in T lymphocyte subsets significantly impact tumor recurrence and postoperative recovery; therefore, identifying optimal strategies to maintain these immune parameters is essential for improving cancer surgery outcom…
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet clinical responses remain highly variable, and microbiome-associated findings lack reproducibility across studies. Increasing evidence implicates the gut microbiome in modulating …
IntroductionAccessible biomarkers that reflect immune-inflammatory activity may support the diagnosis and monitoring of patients with rheumatic diseases (RDs). We conducted a systematic review and meta-analysis to investigate the systemic immune-inflam…
BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment; however, durable clinical benefit is limited to a subset of patients. Long non-coding RNAs (lncRNAs) have emerged as important regulators of tumor biology and immune re…
ObjectiveThis study aims to summarize and appraise the credibility of existing epidemiological evidence on the association between periodontal diseases (PDs) and the risk of site-specific cancers.MethodsPubMed, Embase, and Cochrane Library were searche…
Immune checkpoint inhibitor (ICI) therapy for colorectal cancer (CRC) can be accompanied by endocrine adverse events, yet the comparative risk across commonly used regimens remains unclear. We therefore conducted a network meta-analysis of randomized c…
BackgroundDespite the proven efficacy of KRAS G12C inhibitors (KRAS G12Ci) in solid tumors, evidence from direct comparisons with standard of care is scarce, and no analysis has investigated the potential immunological basis for differential responses….
